Becton Dickinson and Company (US), Baxter International (US), Schott AG (Germany), Eli Lilly and Company (US), Pfizer (US), Gerresheimer AG (Germany), Terumo Corporation (Japan), Antares Pharma Inc. (US), Novo Nordik (Denmark), Sanofi SA (France), Unilife Corporation (US), Zogenix Inc. (US), Hospira Inc. (US), Presage Bioscience (US), MicroCHIPS Inc. (US), Pearl Therapeutics Inc. (US), Genentech Inc. (US), Bend Research (US) are some of the prominent players at the forefront of competition in the Global Injectable Drug Delivery Devices Market and are profiled in MRFR Analysis.
Injectable Drug Delivery Devices – Market Overview
Injectable drug delivery devices are the devices used to administer drugs into the circulatory system. It is the most effective and common route for the administration of most therapeutic agents to ensure a quick response.
Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1211 .
Rapid increase in cancer prevalence rate is the major factor for the growth of the market. Global injectable drug delivery devices market is highly driven by increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle stick injuries. Technological advancements, improving patient compliance, beneficial reimbursement policies, increasing healthcare awareness & increasing geriatric population has also contributed to the growth of the market
25-October-2017: As a part of strategic expansion, Becton Dickinson breaks ground on $60 Million Expansion of Nebraska Manufacturing Facility. Becton Dickinson and Company, was joined by Gov. Pete Ricketts and other state and local leaders to break ground on a $60 million upgrade of its Columbus-East facility. The 69,000 sq. ft. expansion will transform the Columbus-East facility into the flagship plastic injection molding manufacturing facility for BD, and it will become one of the largest and most sophisticated plastic molding plants in the world. The project is expected to be completed by 2021.
26-September-2017: BD expands efforts to combat antimicrobial resistance with new diagnostic test in Europe. Becton Dickinson and Company, announced the launch1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenix™ automated microbiology system in Europe, the new BD Phoenix™ CPO detect test will help hospitals identify and contain infections caused by CPO, while potentially combating an increase in antimicrobial resistance (AMR).
19-September-2017: Becton Dickinson introduces new 6mm pen needle for injection pens. Becton Dickinson and Company, a leading global medical technology company, announced the introduction of the BD Ultra-Fine™ micro pen needle 6mm x 32G for use with leading pen injection devices that is set for distribution. With this launch, BD is providing health care practitioners with an additional needle length option manufactured with BD quality and reliability to provide a wider variety of needle lengths for people with diabetes who inject insulin. The introduction of the new pen needle rounds out the BD Ultra-Fine™ pen needle portfolio, which now includes 4mm x 32G, 5mm x 31G, 6mm x 32G, 8mm x 31G and 12.7mm x 29G. BD Ultra-Fine micro 6mm pen needles are covered at the preferred co-pay by most insurance plans including Medicare part D and are compatible with leading pen injection devices.
Order Single User License Copy of 80 Premium Pages is Available @ https://www.marketresearchfuture.com/reports/injectable-drug-delivery-devices-market-1211 .
Injectable Drug Delivery Devices Market – Competitive Analysis
As the market seems to be attractive, growing and profitable, at the same time market has witnessed intense rivalry among existing competitors. Many new entrants expected to enter into Injectable Drug Delivery Devices market. There are many big players in the Injectable Drug Delivery Devices market such as: Becton Dickinson and Company (US), Baxter International (US), Schott AG (Germany), Eli Lilly and Company (US), Pfizer (US), Gerresheimer AG (Germany), Terumo Corporation (Japan), Antares Pharma, Inc. (US), Novo Nordik (Denmark), Sanofi SA (France), Unilife Corporation (US), Zogenix, Inc (US), Hospira, Inc (US), Presage Bioscience (US), MicroCHIPS, Inc (US), Pearl Therapeutics Inc (US), Genentech Inc. (US), Bend Research (US).
Leading players: – Becton Dickinson and company is going to dominate the injectable drug delivery market following by Pfizer & Baxter International, Inc.
Injectable Drug Delivery Devices Market – Regional Analysis
Global injectable drug delivery devices market is dominated by America owning to increasing patient population suffering from chronic diseases such as: diabetes & cancer. Increasing aging population & technological development is also supporting the growth of the market. Europe accounts second largest market for injectable drug delivery devices which is followed by Asia Pacific. Huge patient population & rapid development of economies in countries of Asia Pacific is the major driver for the market in this region.
- Research Methodology
- Market Dynamics
- Market Factor Analysis
- Global Injectable Drug Delivery Devices, By Route Of Administration
- Global Injectable Drug Delivery Devices, By Devices
- Global Injectable Drug Delivery Devices, By Utility
- Global Injectable Drug Delivery Devices, By End Users
- Global Injectable Drug Delivery Devices, By Region
- Competitive Landscape
- Company Profile
Ask to Expert @ https://www.marketresearchfuture.com/enquiry/1211 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312